Immunohistochemical Expression of Cyclin D1 in Renal Cell Carcinoma Subtypes

Zahraa Marwan Al-Omar; Payman Mohammadsalih Salim; Khalid Wissam Abdulfattah Khattab; Maram Abdaljaleel

doi:10.54133/ajms.v7i1.1257

Authors

Zahraa Marwan Al-Omar Department of Pathology, College of Medicine, University of Mosul, Mosul, Iraq
Payman Mohammadsalih Salim Department of Pathology, Medicolegal Institute, Hawler, Kurdistan Region, Iraq https://orcid.org/0009-0004-1007-9354
Khalid Wissam Abdulfattah Khattab Department of Pathology, College of Medicine, University of Mosul, Mosul, Iraq https://orcid.org/0000-0003-4364-0676
Maram Abdaljaleel Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman, Jordan; Department of Clinical Laboratories and Forensic Medicine, Jordan University Hospital, Amman, Jordan https://orcid.org/0000-0002-9257-2596

DOI:

https://doi.org/10.54133/ajms.v7i1.1257

Keywords:

Cyclin D1, Immunohistochemistry, Renal cell carcinoma subtypes

Abstract

Background: Renal cell carcinoma (RCC) is the second-leading cause of mortality among urological malignancies and accounts for 2–3% of adult malignancies. Approximately 25% of patients experienced recurrence or metastasis subsequent to surgery, accompanied by radiation and chemotherapy failure. Cyclin D1, a critical regulator of the Growth/Synthesis (G1/S) transition, is a subject of significant research. Objectives: To assess the frequency of immunohistochemical expression of cyclin D1 in RCC subtypes and its association with some clinicopathological parameters such as age, gender, size of tumor, histological type, and grade. Methods: During a period of eleven months extending from March 2023 through January 2024, 64 RCC cases were included in this retrospective case series study, obtained from the histopathological departments of private laboratories in Mosul city, Iraq. An immunohistochemistry investigation using Cyclin D1 was performed, and data of the positive cyclin D1 expression were evaluated. Results: The mean age was 54.8 years, with male predominance (53%). Renal cell carcinoma cases included in this study show immunohistochemical expression of Cyclin D1, but with different staining grades. 39% were low expressers, versus 61% were high expressers. Cyclin D1 expression showed a significant association with age, histological type, tumor size, and nuclear grade, respectively. Conclusions: Cyclin D1 is overexpressed in renal cell carcinoma, and targeting it may benefit treatment and prevention. In renal cell cancer, cyclin D1 expression is associated with a favorable prognosis and can aid in predicting patient outcomes.

Downloads

Download data is not yet available.

References

Deng H, Huang C, Wang Y, Jiang H, Peng S, Zhao X. LINC00511 promotes the malignant phenotype of clear cell renal cell carcinoma by sponging microRNA-625 and thereby increasing cyclin D1 expression. Aging (Albany NY). 2019;11(16):5975-5991. doi: 10.18632/aging.102156.

Wang QS, Li F, Liao ZQ, Li K, Yang XL, Lin YY, et al. Low level of Cyclin-D1 correlates with worse prognosis of clear cell renal cell carcinoma patients. Cancer Med. 2019;8(9):4100-4109. doi: 10.1002/cam4.2313.

Qin Z, Hu H, Sun W, Chen L, Jin S, Xu Q, et al. miR-224-5p contained in urinary extracellular vesicles regulates PD-L1 expression by inhibiting cyclin D1 in renal cell carcinoma cells. Cancers (Basel). 2021;13(4):618. doi: 10.3390/cancers13040618.

Li Z, Liu J, Zhang X, Fang L, Zhang C, Zhang Z, et al. Prognostic significance of cyclin D1 expression in renal cell carcinoma: a systematic review and meta-analysis. Pathol Oncol Res. 2020;26(3):1401-1409. doi: 10.1007/s12253-019-00776-0.

Zhang J, Sun Y, Tang K, Xu H, Xiao J, Li Y. RGC32 promotes the progression of ccRCC by activating the NF-κB/SHP2/EGFR signaling pathway. Aging (Albany NY). 2024;16. doi: 10.18632/aging.205890.

Kowalewski A, Borowczak J, Maniewski M, Gostomczyk K, Grzanka D, Szylberg Ł. Targeting apoptosis in clear cell renal cell carcinoma. Biomed Pharmacother. 2024;175:116805. doi: 10.1016/j.biopha.2024.116805.

Kadhim DA. The dysregulation of cyclin dependent kinase regulators role in SV40 related renal cell carcinoma. South Asian J Res Microbiol. 2024;18(1):8-17. doi: 10.9734/sajrm/2024/v18i1339.

Li Y, Xiao X, Chen H, Chen Z, Hu K, Yin D. Transcription factor NFYA promotes G1/S cell cycle transition and cell proliferation by transactivating cyclin D1 and CDK4 in clear cell renal cell carcinoma. Am J Cancer Res. 2020;10(8):2446-2463. PMID:32905496.

Yang J, Zhong X, Gao X, Xie W, Chen Y, Liao Y, et al. Knockdown of PIK3R6 impedes the onset and advancement of clear cell renal cell carcinoma. Cell Adh Migr. 2024;18(1):1-12. doi: 10.1080/19336918.2024.2353920.

Montalto FI, De Amicis F. Cyclin D1 in cancer: A molecular connection for cell cycle control, adhesion and invasion in tumor and stroma. Cells. 2020;9(12):2648. doi: 10.3390/cells9122648.

Dar MS, Abbas R, Shah Z, Latoo SH, Gowhar O. Immunohistochemical expression of E-Cadherin and Cyclin D1 in different grades of oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2023;27(3):476-480. doi: 10.4103/jomfp.jomfp_257_23.

Abdelnaby AA, Azzam EA, E Al Nashar AT. Immunohistochemical expression of cyclin D1 in breast carcinoma. Egypt J Hosp Med. 2022;87(1):2082-2090. doi: 10.21608/ejhm.2022.232822.

González-Ruiz L, González-Moles MÁ, González-Ruiz I, Ruiz-Ávila I, Ayén Á, Ramos-García P. An update on the implications of cyclin D1 in melanomas. Pigment Cell Melanoma Res. 2020;33(6):788-805. doi: 10.1111/pcmr.12874.

Yildirim HT, Nergiz D, Sadullahoglu C, Akgunduz Z, Yildirim S, Dogan S, et al. The extent of cyclin D1 expression in endometrial pathologies and relevance of cyclin D1 with the clinicopathological features of endometrioid endometrial carcinoma. Indian J Pathol Microbiol. 2020;63(3):412-417. doi: 10.4103/IJPM.IJPM_589_19.

Mahzouni P, Taheri F. An immunohistochemical study of cyclin D1 expression in astrocytic tumors and its correlation with tumor grade. Iran J Pathol. 2019;14(3):252-257. doi: 10.30699/ijp.2019.82024.1771.

Roshdy RG, Said EM. Expression and prognostic significance of cyclin D1 and cyclooxygenase-2 in colorectal carcinoma: An immunohistochemical study. Egypt J Pathol. 2022 ;42(1):44-51. doi: 10.4103/egjp.egjp_10_22.

Cahyanur R, Utari AP, Rahadiani N. Cyclin D1 expression, clinicopathological characteristics, and 2-year survival rate of gastric cancer in Cipto Mangunkusumo General Hospital. Niger J Clin Pract. 2023;26(8):1057-1062. doi: 10.4103/njcp.njcp_222_22.

Khalesi S, Maleki L, Eskandari S, Dehabadi FZ, Kohpaee AY. Cyclin D1 and Ki-67 expression and its correlation with histopathological parameters and cervical lymph node metastasis in oral squamous cell carcinoma. Dent Res J (Isfahan). 2023;20:112. PMID: 38020247.

Karim S, Al-Maghrabi JA, Farsi HM, Al-Sayyad AJ, Schulten HJ, Buhmeida A, et al. Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia. BMC Cancer. 2016;16(Suppl 2):741. doi: 10.1186/s12885-016-2775-2.

Lima MS, Pereira RA, Costa RS, Tucci S, Dantas M, Muglia VF, et al. The prognostic value of cyclin D1 in renal cell carcinoma. Int Urol Nephrol. 2014;46(5):905-913. doi: 10.1007/s11255-013-0602-0.

Rizwan M, Farooq N, Tariq H, Akhtar AN, Ibne-Rasa SN, Naz S. To study the association of cyclin D1 expression with Fuhrman’s nuclear grading in renal cell carcinoma. Pakistan J Med Health Sci. 2022;16(07):96. doi: 10.53350/pjmhs2216796

Kwiatkowski M, Krajewski A, Durślewicz J, Buchholz K, Grzanka D, Gagat M, et al. Overexpression of cyclin F/CCNF as an independent prognostic factor for poor survival in clear cell renal cell carcinoma. Sci Rep. 2024;14(1):9280. doi: 10.1038/s41598-024-59437-1.

Latic D, Pejic S, Savic S, Loncar Z, M Nikolic I, Nikolic G, et al. Cyclin D1 and p57 expression in relation to clinicopathological characteristics and overall survival in patients with renal cell carcinoma. J BUON. 2019;24(1):301-309. PMID: 30941985.

Xue J, Qin Z, Li X, Zhang J, Zheng Y, Xu W, et al. Genetic polymorphisms in cyclin D1 are associated with risk of renal cell cancer in the Chinese population. Oncotarget. 2017;8(46):80889-80899. doi:10.18632/oncotarget.20720.

Ghafour YM, Yousef IH, Ali SA, Murad MM. Immunohistochemical expression of Napsin A, CD82 and Cyclin D1 in some renal tumors. Egypt J Hosp Med. 2018;71(7):3616-3621. doi: 10.12816/0047683.

Mandrekar S, Amoncar S, Raiturkar SP, Prabhudesai M, Pinto RW. A histopathological study of renal cell carcinoma at a tertiary care hospital. Indian J Pathol Oncol. 2021;8:193-197. doi: 10.18231/j.ijpo.2021.038.